2110 NARCISSUS CT, VENICE, CA
Changes in Board, Management or Compensation
Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
News, Material Contracts
Annual Report to Security Holders
Shareholder Director Nominations
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Other Events
Announces Closing of $5 Million Public Offering
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities